Skip to main content

Advertisement

SpringerLink
Log in

Therapy of non-Hodgkin's lymphoma

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Non-Hodgkin's lymphomas are a heterogeneous group of malignancies of the lymphoid system. The exact etiology for most lymphomas has not been determined, but both viral and bacterial infections have been shown to be important etiologic factors. The WHO classification of hematopoietic and lymphoid tumours classifies lymphomas into B-cell and T-cell neoplasms. B-cell lymphomas account for more than 85% of all lymphomas. The Ann Arbor staging classification has been adopted by the AJCC and UICC as a standard for classifying extent of anatomic disease. The two most common histologic disease entities are follicular lymphomas and diffuse large B-cell lymphomas. The management of follicular lymphomas is used as a paradigm for the management of all indolent lymphomas. Radiation therapy is used for stage I and II disease, while alkylating agent chemotherapy, immunotherapy and radioimmunotherapy are most frequently used in stage III and IV disease that requires treatment. Most patients with follicular lymphoma enjoy prolonged survival, but at present there is no evidence that those with stage III and IV follicular lymphoma can be cured. Diffuse large B-cell lymphomas serve as a paradigm for treating aggressive lymphomas. Stage I and II diffuse large cell lymphomas are generally treated with combined modality therapy with doxorubicin-based chemotherapy followed by involved field radiation therapy, while those with stage III and IV disease are treated with chemotherapy alone. Patients who fail initial management are treated with further chemotherapy. High-dose chemotherapy with stem cell rescue has been shown to be particularly effective as salvage treatment for diffuse large cell lymphomas. The management of a heterogeneous group of primary extranodal lymphomas in general follows the above treatment principles, with additional treatment being required for those with a high risk of CNS failures, or involvement of contralateral paired organs. The management of MALT lymphomas, especially gastric MALT lymphoma, deserves special attention because of the high response rate to Helicobacter pylori eradication therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cancer facts and figures. American Cancer Society, 2002.

  2. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93:824–842.

    Google Scholar 

  3. Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 2002; 94:2015–2023.

    Google Scholar 

  4. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92:1240–1251.

    Google Scholar 

  5. Sant M, Capocaccia R, Coleman MP, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001; 37:1659–1667.

    Google Scholar 

  6. Stolte M, Bayerdorffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut 2002; 50:19iii–24.

    Google Scholar 

  7. Hermine O, Lefrere F, Bronowicki J-P, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89–94.

    Google Scholar 

  8. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514–1516.

    Google Scholar 

  9. Cote TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645–650.

    Google Scholar 

  10. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49:2112–2135.

    Google Scholar 

  11. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361–1392.

    Google Scholar 

  12. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: World Health Organization, 2001.

  13. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31:1860–1861.

    Google Scholar 

  14. Johnson PW, Whelan J, Longhurst S, et al. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer 1993; 67:792–797.

    Google Scholar 

  15. Aviles A, Zepeda G, Diaz-Maqueo JC, et al. Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma. Leuk Lymphoma 1992; 7:135–138.

    Google Scholar 

  16. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987–994.

  17. Tsang RW, Gospodarowicz MK, O'Sullivan B. Staging and management of localized non-Hodgkin's lymphomas: variations among experts in radiation oncology. Int J Radiat Oncol Biol Phys 2002; 52:643–651.

    Google Scholar 

  18. Jaffray DA, Siewerdsen JH, Wong JW, Martinez AA. Flat-panel cone-beam computed tomography for image-guided radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53:1337–1349.

    Google Scholar 

  19. Armitage J, Weisenburger D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780–2795.

    Google Scholar 

  20. Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83:3800–3807.

    Google Scholar 

  21. Gribben JG, Nadler LM. Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction. Important Adv Oncol 1994:117–129.

  22. Gospodarowicz M, Lippuner T, Pintilie M, et al. Stage I and II follicular lymphoma: long-term outcome and pattern of failure following treatment with involved-field radiation therapy alone. Int J Radiat Biol Phys 1999; 45:217a.

    Google Scholar 

  23. MacManus M, Hoppe R. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14:1282–1290.

    Google Scholar 

  24. Pendlebury S, el Awadi M, Ashley S, Brada M, Horwich A. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 1995; 36:167–171.

    Google Scholar 

  25. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825–2833.

    Google Scholar 

  26. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268–276.

    Google Scholar 

  27. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 1993; 329:1608–1614.

    Google Scholar 

  28. Rohatiner A, Radford J, Deakin D, et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001; 85:29–35.

    Google Scholar 

  29. Fisher RI, Dana BW, LeBlanc M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000; 18:2010–2116.

    Google Scholar 

  30. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20:3545–3557.

    Google Scholar 

  31. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453–2463.

    Google Scholar 

  32. Tsang RW, Gospodarowicz MK. Management of localized (stage I and II) clinically aggressive lymphomas. Ann Hematol 2001; 80 Suppl 3:B66–B72.

    Google Scholar 

  33. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339:21–26.

    Google Scholar 

  34. Miller TP, LeBlanc M, Spier C, Chase E, Fischer RI. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. In: Proceedings of American Society of Haematology, 2001, pp 724a–725a.

  35. Horning SJ, Glick JH, Kim K, Earle JD, O'Connell MJ. Final report of E1484: CHOP v CHOP + radiotherapy (RT) for limited stage diffuse aggressive lymphoma. In: Proceedings of American Society of Haematology, 2001, p 724a.

  36. Bonnet C, Fillet G, et al. Radiotherapy is unnecessary in elderly patients with localised aggressive non-Hodgkins lymphoma: results of the LNH 93–4 study. Ann Oncol 2002; 13 Suppl 2.

  37. Cheson BD. CHOP plus rituximab—balancing facts and opinion. N Engl J Med 2002; 346:280–282.

    Google Scholar 

  38. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002–1006.

    Google Scholar 

  39. Itoh K, Ohtsu T, Fukuda H, et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 2002; 13:1347–1355.

    Google Scholar 

  40. Balzarotti M, Spina M, Sarina B, et al. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann Oncol 2002; 13:1341–1346.

    Google Scholar 

  41. Pfreundschuh M, Trumper L, Kloess M, et al. 2-weekly CHOP (CHOP-14): the new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age. Ann Oncol 2002; 13 Suppl 2.

  42. Wilder RB, Rodriguez MA, Tucker SL, et al. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys 2001; 50:743–749.

    Google Scholar 

  43. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235–242.

    Google Scholar 

  44. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52:1410–1416.

    Google Scholar 

  45. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342:575–577.

    Google Scholar 

  46. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357:39–40.

    Google Scholar 

  47. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50:1258–1264.

    Google Scholar 

  48. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95:802–806.

    Google Scholar 

  49. Gospodarowicz M, Wells W. ASTRO Refresher course: extranodal lymphomas. San Francisco, 2001.

  50. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540–1545.

    Google Scholar 

  51. Micallef INM, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18:947–955.

    Google Scholar 

  52. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817–2824.

    Google Scholar 

  53. Branson K, Chopra R, Kottaridis PD, et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20:4022–4031.

    Google Scholar 

  54. The Non-Hodgkin's Lymphoma Classification Project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89:3909–3918.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada

    J. Coffey, D. C. Hodgson & M. K. Gospodarowicz

Authors
  1. J. Coffey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. C. Hodgson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. K. Gospodarowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. K. Gospodarowicz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coffey, J., Hodgson, D.C. & Gospodarowicz, M.K. Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30 (Suppl 1), S28–S36 (2003). https://doi.org/10.1007/s00259-003-1157-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1157-6

Keywords

Search

Navigation